Summit Therapeutics Valuation
| SMMT Stock | USD 19.75 0.31 1.59% |
At this time, the company appears to be overvalued. Summit Therapeutics PLC has a current Real Value of $16.97 per share. The regular price of the company is $19.75. Our model measures the value of Summit Therapeutics PLC from inspecting the company fundamentals such as Shares Owned By Institutions of 12.91 %, shares outstanding of 737.68 M, and Return On Equity of -0.95 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Summit Therapeutics' valuation include:
Price Book 37.4392 | Enterprise Value | Enterprise Value Ebitda (5.32) | Price Sales 753.9008 | Enterprise Value Revenue 6.4 K |
Overvalued
Today
Please note that Summit Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Summit Therapeutics PLC is based on 3 months time horizon. Increasing Summit Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Summit Therapeutics' intrinsic value may or may not be the same as its current market price of 19.75, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.75 | Real 16.97 | Target 32.15 | Hype 19.75 | Naive 19.57 |
The intrinsic value of Summit Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Summit Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Summit Therapeutics PLC helps investors to forecast how Summit stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Summit Therapeutics more accurately as focusing exclusively on Summit Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Summit Therapeutics' intrinsic value based on its ongoing forecasts of Summit Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Summit Therapeutics' closest peers.
Summit Therapeutics Cash |
|
Summit Valuation Drivers Correlation
Many accounts on the financial statements of Summit Therapeutics PLC are highly interrelated and sometimes correlated. Consequently, when conducting Summit's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Summit
Click cells to compare fundamentals
Summit Valuation Trend
Summit Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Summit Therapeutics' financial worth over time. Using both Summit Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Summit Therapeutics Total Value Analysis
Summit Therapeutics PLC is at this time expected to have valuation of 14.15 B with market capitalization of 14.57 B, debt of 7.22 M, and cash on hands of 121.97 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Summit Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
14.15 B | 14.57 B | 7.22 M | 121.97 M |
Summit Therapeutics Asset Utilization
One of the ways to look at asset utilization of Summit is to check how much profit was generated for every dollar of assets it reports. Summit Therapeutics PLC has a negative utilization of assets of -0.41 %, losing $0.004131 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Summit Therapeutics PLC shows how discouraging it operates for each dollar spent on its assets.Summit Therapeutics Ownership Allocation
Summit Therapeutics PLC shows a total of 737.68 Million outstanding shares. Summit Therapeutics PLC has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 84.36 % of Summit Therapeutics outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Summit Therapeutics Profitability Analysis
Net Loss for the year was (221.31 M) with profit before overhead, payroll, taxes, and interest of 705 K.About Summit Therapeutics Valuation
The stock valuation mechanism determines Summit Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Summit Therapeutics PLC based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Summit Therapeutics. We calculate exposure to Summit Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Summit Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -15 M | -14.3 M | |
| Pretax Profit Margin | (128.64) | (122.21) | |
| Operating Profit Margin | (117.71) | (111.82) | |
| Net Loss | (121.45) | (115.38) | |
| Gross Profit Margin | (2.95) | (2.81) |
Summit Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Summit Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 718.5 M |
Summit Therapeutics Current Valuation Indicators
Summit Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Summit Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Summit Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Summit Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Summit Therapeutics' worth.Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.